Role of metabolic characteristics in the co-occurrence of insomnia, Alzheimer’s disease, and Parkinson’s disease: a Mendelian randomization study
ObjectiveThere reportedly exists a significant comorbidity between insomnia and neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), indicative of a potential link to serum metabolic dysregulation.MethodTo elucidate shared pathophysiological mechanisms between i...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Aging Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnagi.2024.1436171/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841558714400636928 |
|---|---|
| author | Chengyong Liu Chi Wang Jing Jiang Yuyang Bo Lixiu Nan Ying Zhang Kongxi Zhu Xiaoqiu Wang Xinxin Feng Xiaoyang Lian Shan Qin |
| author_facet | Chengyong Liu Chi Wang Jing Jiang Yuyang Bo Lixiu Nan Ying Zhang Kongxi Zhu Xiaoqiu Wang Xinxin Feng Xiaoyang Lian Shan Qin |
| author_sort | Chengyong Liu |
| collection | DOAJ |
| description | ObjectiveThere reportedly exists a significant comorbidity between insomnia and neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), indicative of a potential link to serum metabolic dysregulation.MethodTo elucidate shared pathophysiological mechanisms between insomnia and AD/PD, we performed comprehensive two-sample Mendelian randomization (MR) analyses, investigating 1,400 serum metabolic characteristics for their causal relationships with the risks of insomnia, AD, widely defined AD (WDAD), and PD. We employed publicly available genetic data; the primary estimate was determined using inverse-variance weighting, supplemented by weighted median, simple mode, weighted mode, and the MR-PRESSO and MR-Egger methods to evaluate heterogeneity and pleiotropy.ResultsThe ratio of N-palmitoyl-sphingosine to N-palmitoyl-sphinganine is linked to higher risks of insomnia (OR = 1.137, 95% CI = 1.015–1.273, p = 0.026) and AD (OR = 1.090, 95% CI = 1.005–1.183, p = 0.037). The acetylcarnitine to propionylcarnitine ratio is a risk factor for insomnia (OR = 1.190, 95% CI = 1.003–1.370, p = 0.016) but has protective effects against AD (OR = 0.868, 95% CI = 0.784–0.961, p = 0.006) and WDAD (OR = 0.892, 95% CI = 0.817–0.973, p = 0.010). Glutamine conjugate of C7H12O2 levels are associated with reduced risk of insomnia (OR = 0.863, 95% CI = 0.749–0.995, p = 0.042) and PD (OR = 0.856, 95% CI = 0.746–0.981, p = 0.026).ConclusionOur findings highlight the crucial role of serum metabolic characteristics in the comorbidity of insomnia with neurodegenerative diseases, providing valuable insights into prospective therapeutic targets and diagnostic markers. |
| format | Article |
| id | doaj-art-9f0f98da3352418eb48fd166dbe07411 |
| institution | Kabale University |
| issn | 1663-4365 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Aging Neuroscience |
| spelling | doaj-art-9f0f98da3352418eb48fd166dbe074112025-01-06T06:59:36ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652025-01-011610.3389/fnagi.2024.14361711436171Role of metabolic characteristics in the co-occurrence of insomnia, Alzheimer’s disease, and Parkinson’s disease: a Mendelian randomization studyChengyong Liu0Chi Wang1Jing Jiang2Yuyang Bo3Lixiu Nan4Ying Zhang5Kongxi Zhu6Xiaoqiu Wang7Xinxin Feng8Xiaoyang Lian9Shan Qin10Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, ChinaShanghai University of Traditional Chinese Medicine, Shanghai, ChinaJiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, ChinaJiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, ChinaJiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, ChinaJiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, ChinaJiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, ChinaJiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, ChinaNingbo Traditional Chinese Medicine Hospital, Ningbo, Zhejiang Province, ChinaJiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, ChinaJiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, ChinaObjectiveThere reportedly exists a significant comorbidity between insomnia and neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), indicative of a potential link to serum metabolic dysregulation.MethodTo elucidate shared pathophysiological mechanisms between insomnia and AD/PD, we performed comprehensive two-sample Mendelian randomization (MR) analyses, investigating 1,400 serum metabolic characteristics for their causal relationships with the risks of insomnia, AD, widely defined AD (WDAD), and PD. We employed publicly available genetic data; the primary estimate was determined using inverse-variance weighting, supplemented by weighted median, simple mode, weighted mode, and the MR-PRESSO and MR-Egger methods to evaluate heterogeneity and pleiotropy.ResultsThe ratio of N-palmitoyl-sphingosine to N-palmitoyl-sphinganine is linked to higher risks of insomnia (OR = 1.137, 95% CI = 1.015–1.273, p = 0.026) and AD (OR = 1.090, 95% CI = 1.005–1.183, p = 0.037). The acetylcarnitine to propionylcarnitine ratio is a risk factor for insomnia (OR = 1.190, 95% CI = 1.003–1.370, p = 0.016) but has protective effects against AD (OR = 0.868, 95% CI = 0.784–0.961, p = 0.006) and WDAD (OR = 0.892, 95% CI = 0.817–0.973, p = 0.010). Glutamine conjugate of C7H12O2 levels are associated with reduced risk of insomnia (OR = 0.863, 95% CI = 0.749–0.995, p = 0.042) and PD (OR = 0.856, 95% CI = 0.746–0.981, p = 0.026).ConclusionOur findings highlight the crucial role of serum metabolic characteristics in the comorbidity of insomnia with neurodegenerative diseases, providing valuable insights into prospective therapeutic targets and diagnostic markers.https://www.frontiersin.org/articles/10.3389/fnagi.2024.1436171/fullinsomnianeurodegenerative diseasesAlzheimer’s diseaseParkinson’s diseaseMendelian randomization |
| spellingShingle | Chengyong Liu Chi Wang Jing Jiang Yuyang Bo Lixiu Nan Ying Zhang Kongxi Zhu Xiaoqiu Wang Xinxin Feng Xiaoyang Lian Shan Qin Role of metabolic characteristics in the co-occurrence of insomnia, Alzheimer’s disease, and Parkinson’s disease: a Mendelian randomization study Frontiers in Aging Neuroscience insomnia neurodegenerative diseases Alzheimer’s disease Parkinson’s disease Mendelian randomization |
| title | Role of metabolic characteristics in the co-occurrence of insomnia, Alzheimer’s disease, and Parkinson’s disease: a Mendelian randomization study |
| title_full | Role of metabolic characteristics in the co-occurrence of insomnia, Alzheimer’s disease, and Parkinson’s disease: a Mendelian randomization study |
| title_fullStr | Role of metabolic characteristics in the co-occurrence of insomnia, Alzheimer’s disease, and Parkinson’s disease: a Mendelian randomization study |
| title_full_unstemmed | Role of metabolic characteristics in the co-occurrence of insomnia, Alzheimer’s disease, and Parkinson’s disease: a Mendelian randomization study |
| title_short | Role of metabolic characteristics in the co-occurrence of insomnia, Alzheimer’s disease, and Parkinson’s disease: a Mendelian randomization study |
| title_sort | role of metabolic characteristics in the co occurrence of insomnia alzheimer s disease and parkinson s disease a mendelian randomization study |
| topic | insomnia neurodegenerative diseases Alzheimer’s disease Parkinson’s disease Mendelian randomization |
| url | https://www.frontiersin.org/articles/10.3389/fnagi.2024.1436171/full |
| work_keys_str_mv | AT chengyongliu roleofmetaboliccharacteristicsinthecooccurrenceofinsomniaalzheimersdiseaseandparkinsonsdiseaseamendelianrandomizationstudy AT chiwang roleofmetaboliccharacteristicsinthecooccurrenceofinsomniaalzheimersdiseaseandparkinsonsdiseaseamendelianrandomizationstudy AT jingjiang roleofmetaboliccharacteristicsinthecooccurrenceofinsomniaalzheimersdiseaseandparkinsonsdiseaseamendelianrandomizationstudy AT yuyangbo roleofmetaboliccharacteristicsinthecooccurrenceofinsomniaalzheimersdiseaseandparkinsonsdiseaseamendelianrandomizationstudy AT lixiunan roleofmetaboliccharacteristicsinthecooccurrenceofinsomniaalzheimersdiseaseandparkinsonsdiseaseamendelianrandomizationstudy AT yingzhang roleofmetaboliccharacteristicsinthecooccurrenceofinsomniaalzheimersdiseaseandparkinsonsdiseaseamendelianrandomizationstudy AT kongxizhu roleofmetaboliccharacteristicsinthecooccurrenceofinsomniaalzheimersdiseaseandparkinsonsdiseaseamendelianrandomizationstudy AT xiaoqiuwang roleofmetaboliccharacteristicsinthecooccurrenceofinsomniaalzheimersdiseaseandparkinsonsdiseaseamendelianrandomizationstudy AT xinxinfeng roleofmetaboliccharacteristicsinthecooccurrenceofinsomniaalzheimersdiseaseandparkinsonsdiseaseamendelianrandomizationstudy AT xiaoyanglian roleofmetaboliccharacteristicsinthecooccurrenceofinsomniaalzheimersdiseaseandparkinsonsdiseaseamendelianrandomizationstudy AT shanqin roleofmetaboliccharacteristicsinthecooccurrenceofinsomniaalzheimersdiseaseandparkinsonsdiseaseamendelianrandomizationstudy |